Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights

Following trial pauses by Novartis and Bristol Myers Squibb due to safety concerns, rheumatologist confidence in autologous CAR T dropped significantly from 7.5 to 5.2 on a 10-point scale. Despite this, autologous CAR T retained its lead among immune reset modalities at 49% preference. Systemic sclerosis emerged as the clearest near-term opportunity, while delivery infrastructure and safety evidence are now critical differentiators for market adoption.

10/01/2026, 1:53 PM • GlobeNewswire

Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.

09/30/2026, 4:58 AM • GlobeNewswire

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.

09/30/2026, 4:54 AM • GlobeNewswire

Novo Nordisk Gives Uninspiring Outlook

Novo Nordisk provided disappointing guidance to investors, forecasting a considerable slowdown in revenue growth. The company faces challenges including the patent cliff for its blockbuster drug Ozempic, which management acknowledged as a significant concern.

09/29/2026, 11:26 PM • The Motley Fool

Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two pharmaceutical giants with divergent strategies: Bristol Myers Squibb, a deep-value dividend payer trading at cheap multiples (P/E 14.07) with flat revenue but stabilizing earnings, versus Eli Lilly, a high-growth juggernaut riding explosive success in GLP-1 metabolic drugs with 45% revenue growth and a P/E of 40.26. Despite BMY's attractive valuation, the author recommends LLY for 2026 due to its strong growth trajectory, successful drug pipeline including Retatrutide and lipoprotein(a) therapeutics, and forecast for 30% revenue growth.

09/29/2026, 6:22 PM • The Motley Fool

3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation

Bristol Myers Squibb trades at a low P/E ratio of 9 despite a 42.5% stock surge over the past year, reflecting investor uncertainty about its ability to offset major patent expirations. However, the company's strong growth portfolio (up 15%) and new drug launches suggest successful patent cliff mitigation, potentially offering upside if 2027-2028 results exceed expectations.

09/29/2026, 5:21 AM • The Motley Fool

Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks.

Federal Reserve Chair Kevin Warsh's hawkish stance signals sustained higher interest rates to combat inflation. While this increases competition for dividend stocks from Treasury bonds, big pharma dividend stocks like Pfizer, AbbVie, and Bristol Myers Squibb should remain resilient due to strong fundamentals and manageable debt service costs. Historical data shows pharma-specific business factors matter more than interest rates for stock performance.

09/27/2026, 5:30 AM • The Motley Fool

Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

09/24/2026, 1:00 PM • GlobeNewswire

Onco360® is a participating specialty pharmacy in the ZENBEXUS™ (iberdomide) limited dispense network

Onco360, the nation's leading independent specialty pharmacy, has been selected by Bristol-Myers Squibb as a participating pharmacy in the limited dispense network for ZENBEXUS™ (iberdomide), a cereblon-modulating protein degrader used to treat relapsed or refractory multiple myeloma. The drug demonstrated a 41% MRD-negative complete response rate in the EXCALIBER-RRMM trial compared to 21% in the comparator arm.

09/21/2026, 5:00 PM • GlobeNewswire

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder

Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy drugs. With a 3.95% dividend yield, $5B buyback program, and potential acquisition interest from AstraZeneca, analysts see significant upside potential as the market has underpriced the stock relative to its pipeline execution.

09/20/2026, 8:30 AM • The Motley Fool

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.

09/18/2026, 9:15 AM • The Motley Fool

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

09/17/2026, 6:49 AM • GlobeNewswire

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand

The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.

09/16/2026, 4:55 AM • GlobeNewswire

Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities

The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.

09/15/2026, 6:40 AM • GlobeNewswire

SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026

Bristol Myers Squibb's SOTYKTU (deucravacitinib), a first-in-class TYK2 inhibitor, has received FDA approval for psoriatic arthritis in March 2026, expanding its commercial potential beyond plaque psoriasis. The drug demonstrates sustained efficacy with PASI 75 response rates of 67%-73% through five years and over 5,000 patient-years of safety data. Market analysis forecasts SOTYKTU sales across seven major markets through 2034, with growth driven by oral convenience, selective mechanism of action, and potential expansion into additional immune-mediated inflammatory disease indications including lupus, Sjogren's syndrome, and Crohn's disease.

09/09/2026, 5:50 AM • GlobeNewswire